S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 83 200 KRW -2.92% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ST Pharm Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Income from Continuing Operations
â‚©30.1B
CAGR 3-Years
90%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Income from Continuing Operations
â‚©1T
CAGR 3-Years
45%
CAGR 5-Years
34%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Income from Continuing Operations
-â‚©54.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Income from Continuing Operations
-â‚©8.7B
CAGR 3-Years
19%
CAGR 5-Years
3%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Income from Continuing Operations
-â‚©2.9B
CAGR 3-Years
58%
CAGR 5-Years
-11%
CAGR 10-Years
9%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Income from Continuing Operations
-â‚©22.9B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
97 768.06 KRW
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
30.1B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Income from Continuing Operations amounts to 30.1B KRW.

What is ST Pharm Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
90%

Over the last year, the Income from Continuing Operations growth was 216%. The average annual Income from Continuing Operations growth rates for ST Pharm Co Ltd have been 90% over the past three years .

Back to Top